BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16166190)

  • 1. Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.
    Dinca O; Paul M; Spencer NJ
    J Psychopharmacol; 2005 Sep; 19(5):521-32. PubMed ID: 16166190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
    Williams K; Brignell A; Randall M; Silove N; Hazell P
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004677. PubMed ID: 23959778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
    Strauss WL; Unis AS; Cowan C; Dawson G; Dager SR
    Am J Psychiatry; 2002 May; 159(5):755-60. PubMed ID: 11986128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders.
    Posey DJ; McDougle CJ
    Harv Rev Psychiatry; 2000; 8(2):45-63. PubMed ID: 10902094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of pervasive developmental disorders in children and adolescents.
    Masi G
    CNS Drugs; 2004; 18(14):1031-52. PubMed ID: 15584771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability.
    Kolevzon A; Mathewson KA; Hollander E
    J Clin Psychiatry; 2006 Mar; 67(3):407-14. PubMed ID: 16649827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of selective serotonin reuptake inhibitors in autism and related disorders.
    Posey DJ; Erickson CA; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):181-6. PubMed ID: 16553538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Use of selective serotonin reuptake inhibitors in children with pervasive developmental disorder: risk of treatment emergent mania'.
    Bates G; Willson SW
    Dev Med Child Neurol; 2003 May; 45(5):359; author reply 360. PubMed ID: 12729153
    [No Abstract]   [Full Text] [Related]  

  • 10. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.
    Politte LC; McDougle CJ
    Psychopharmacology (Berl); 2014 Mar; 231(6):1023-36. PubMed ID: 23552907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy in children and adolescents with pervasive developmental disorders.
    Scahill L; Koenig K
    J Child Adolesc Psychiatr Nurs; 1999; 12(1):41-3. PubMed ID: 10347430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics in children with pervasive developmental disorders.
    Chavez B; Chavez-Brown M; Sopko MA; Rey JA
    Paediatr Drugs; 2007; 9(4):249-66. PubMed ID: 17705564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.
    Jensen PS; Buitelaar J; Pandina GJ; Binder C; Haas M
    Eur Child Adolesc Psychiatry; 2007 Mar; 16(2):104-20. PubMed ID: 17075688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
    Mochcovitch MD; Nardi AE
    Expert Rev Neurother; 2010 Aug; 10(8):1285-93. PubMed ID: 20662754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvoxamine treatment of a child with severe PDD: a single case study.
    Kauffmann C; Vance H; Pumariega AJ; Miller B
    Psychiatry; 2001; 64(3):268-77. PubMed ID: 11708052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopharmacology of autistic spectrum disorders in children and adolescents.
    Nazeer A
    Pediatr Clin North Am; 2011 Feb; 58(1):85-97, x. PubMed ID: 21281850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
    Okada T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):992-8. PubMed ID: 22292193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.